Bryn Mawr Trust CO Abb Vie Inc. Transaction History

Bryn Mawr Trust CO

$2.54 Billion
Q2 2024

A detailed history of Bryn Mawr Trust CO transactions in Abb Vie Inc. stock. As of the latest transaction made, Bryn Mawr Trust CO holds 31,992 shares of ABBV stock, worth $5.28 Million. This represents 0.22% of its overall portfolio holdings.

Number of Shares

31,992

Previous 33,059 3.23%

Holding current value

$5.28 Million

Previous $6.02 Million 8.85%

% of portfolio

0.22%

Previous 0.24%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 08, 2024	SELL	$154.79 - $180.76 $165,160 - $192,870	-1,067 Reduced 3.23%	31,992 $5.49 Million
Q1 2024 May 14, 2024	SELL	$159.82 - $182.1 $307,493 - $350,360	-1,924 Reduced 5.5%	33,059 $6.02 Million
Q3 2023 Nov 15, 2023	SELL	$133.59 - $154.65 $79,085 - $91,552	-592 Reduced 1.66%	34,983 $5.21 Million
Q2 2023 Aug 11, 2023	BUY	$132.51 - $164.9 $98,189 - $122,190	741 Added 2.13%	35,575 $4.79 Million
Q1 2023 May 15, 2023	SELL	$144.61 - $166.54 $74,329 - $85,601	-514 Reduced 1.45%	34,834 $5.55 Million
Q4 2022 Feb 10, 2023	SELL	$138.31 - $165.87 $168,461 - $202,029	-1,218 Reduced 3.33%	35,348 $5.71 Million
Q3 2022 Nov 14, 2022	BUY	$134.21 - $153.93 $71,533 - $82,044	533 Added 1.48%	36,566 $4.91 Million
Q2 2022 Aug 11, 2022	SELL	$137.62 - $174.96 $267,670 - $340,297	-1,945 Reduced 5.12%	36,033 $5.52 Million
Q1 2022 May 16, 2022	SELL	$131.98 - $163.75 $29,167 - $36,188	-221 Reduced 0.58%	37,978 $6.16 Million
Q4 2021 Feb 10, 2022	SELL	$107.43 - $135.93 $125,800 - $159,174	-1,171 Reduced 2.97%	38,199 $5.17 Million
Q3 2021 Oct 26, 2021	SELL	$106.4 - $120.78 $47,986 - $54,471	-451 Reduced 1.13%	39,370 $4.25 Million
Q2 2021 Jul 29, 2021	BUY	$105.21 - $117.21 $169,598 - $188,942	1,612 Added 4.22%	39,821 $4.49 Million
Q1 2021 Apr 23, 2021	SELL	$102.3 - $112.62 $104,243 - $114,759	-1,019 Reduced 2.6%	38,209 $4.14 Million
Q4 2020 Feb 11, 2021	SELL	$80.49 - $108.67 $95,863 - $129,425	-1,191 Reduced 2.95%	39,228 $4.2 Million
Q3 2020 Nov 12, 2020	SELL	$85.91 - $100.83 $111,683 - $131,079	-1,300 Reduced 3.12%	40,419 $3.54 Million
Q2 2020 Aug 13, 2020	SELL	$73.37 - $98.18 $52,386 - $70,100	-714 Reduced 1.68%	41,719 $4.1 Million
Q1 2020 May 08, 2020	BUY	$64.5 - $97.79 $213,043 - $323,000	3,303 Added 8.44%	42,433 $3.23 Million
Q4 2019 Feb 11, 2020	SELL	$72.13 - $90.25 $243,222 - $304,323	-3,372 Reduced 7.93%	39,130 $3.47 Million
Q3 2019 Oct 24, 2019	BUY	$62.98 - $75.72 $37,032 - $44,523	588 Added 1.4%	42,502 $3.22 Million
Q2 2019 Aug 15, 2019	SELL	$65.7 - $83.98 $153,343 - $196,009	-2,334 Reduced 5.27%	41,914 $3.05 Million
Q1 2019 May 15, 2019	BUY	$77.14 - $90.79 $371,506 - $437,244	4,816 Added 12.21%	44,248 $3.57 Million
Q4 2018 Feb 15, 2019	BUY	$77.85 - $96.01 $86,724 - $106,955	1,114 Added 2.91%	39,432 $3.64 Million
Q3 2018 Aug 28, 2019	BUY	$88.91 - $98.84 $3,556 - $3,953	40 Added 0.1%	38,318 $3.62 Million
Q3 2018 Nov 15, 2018	SELL	$88.91 - $98.84 $52,634 - $58,513	-592 Reduced 1.52%	38,278 $3.62 Million
Q2 2018 Aug 28, 2019	BUY	$89.78 - $106.23 $3,591 - $4,249	40 Added 0.1%	38,870 $3.6 Million
Q2 2018 Aug 14, 2018	SELL	$89.78 - $106.23 $22,534 - $26,663	-251 Reduced 0.64%	38,830 $3.6 Million
Q1 2018 Aug 28, 2019	BUY	$92.01 - $123.21 $7,360 - $9,856	80 Added 0.21%	39,081 $3.7 Million
Q1 2018 May 15, 2018	SELL	$92.01 - $123.21 $37,080 - $49,653	-403 Reduced 1.02%	39,001 $3.69 Million
Q4 2017 Aug 28, 2019	BUY	$89.56 - $98.21 $537 - $589	6 Added 0.02%	39,404 $3.81 Million
Q4 2017 Feb 15, 2018	SELL	$89.56 - $98.21 $121,264 - $132,976	-1,354 Reduced 3.32%	39,398 $3.81 Million
Q3 2017 Nov 14, 2017	BUY	$69.85 - $89.22 $2.85 Million - $3.64 Million	40,752	40,752 $3.62 Million

Others Institutions Holding ABBV

# of Institutions

3,841

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $292B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bryn Mawr Trust CO, based on Form 13F filings with the SEC.

News

Stay updated on Bryn Mawr Trust CO with notifications on news.

Account

Bryn Mawr Trust CO Abb Vie Inc. Transaction History